All In Biotech

NDA 212268 · Hisamitsu

Secuado

Asenapine · Transdermal · Atypical Antipsychotic

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 11, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

51

35 Phase 3, 0 recruiting

FAERS reports

912

722 serious, 139 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Jan 30, 2025.

SECUADO is indicated for the treatment of adults with schizophrenia [ see Clinical Studies (14) ]. SECUADO is an atypical antipsychotic indicated for the treatment of adults with schizophrenia. ( 1 )

Mechanism: The mechanism of action of asenapine in schizophrenia is unclear. However, it’s efficacy in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SECUADO · ASENAPINE 5.7MG/24HR · SYSTEM, TRANSDERMAL · Prescription
  • SECUADO · ASENAPINE 7.6MG/24HR · SYSTEM, TRANSDERMAL · Prescription
  • SECUADO · ASENAPINE 3.8MG/24HR · SYSTEM, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Asenapine" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective115
  • drug interaction87
  • off label use74
  • completed suicide73
  • toxicity to various agents67
  • myocarditis58
  • sedation40
  • depression36
  • somnolence32
  • suicidal ideation32
  • product substitution issue31
  • weight increased31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201011
201118
201220
201319
201466
201593
201688
201752
201828
201947
202045
202174
2022101
202362
202449
202589
202650

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Secuado (Asenapine)

2024 spending

$6.1M

Beneficiaries

873

4,499 claims

Per beneficiary

$6,973

$48.16 per unit

View as table
YearSpending
2020$565,151
2021$2,179,911
2022$3,738,479
2023$4,972,991
2024$6,087,666

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 119 on PubMed

Sponsor: Hisamitsu

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.